Thurston Springer Miller Herd & Titak’s Novo Nordisk NVO Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.6K	Hold	472	–	–	0.01%	657
2026 Q1	$17.3K	Hold	472	–	–	0.01%	795
2025 Q4	$24K	Buy	+472	New	+$24.1K	0.01%	696
2025 Q3	–	Sell	-1,356	Closed	-$93.6K	–	1095
2025 Q2	$93.6K	Buy	1,356 +428	+46%	+$29.1K	0.01%	521
2025 Q1	$64.5K	Buy	928 +143	+18%	+$11.8K	0.01%	556
2024 Q4	$67.6K	Buy	785 +271	+53%	+$29.3K	0.01%	462
2024 Q3	$61.3K	Buy	514 +61	+13%	+$8.13K	0.02%	512
2024 Q2	$64.7K	Buy	+453	New	+$60K	0.02%	503

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

GIM

Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return

CFB

Cullen/Frost Bankers San Antonio, Texas $10.1B AUM 29.18% 1-Year Est. Return

OFA

Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's NVO Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Novo Nordisk (NVO) position steady in Q2 2026 at 472 shares worth $22.6K. The position accounts for 0.01% of the portfolio, ranked #657.

Thurston Springer Miller Herd & Titak first reported a position in NVO in Q2 2024 and has held it in 8 quarters since. The position peaked at $93.6K in Q2 2025. 516 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Thurston Springer Miller Herd & Titak held 472 shares of Novo Nordisk worth $22.6K as of Q2 2026.
Thurston Springer Miller Herd & Titak left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #657 holding.
Thurston Springer Miller Herd & Titak first reported a position in Novo Nordisk in Q2 2024 and has held it in 8 quarters since.
Thurston Springer Miller Herd & Titak's Novo Nordisk position peaked at $93.6K in Q2 2025.
516 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.